Advancing OCT evaluation to reveal early-stage changes in glaucoma
Advancing OCT evaluation to reveal early-stage changes in glaucoma
批准号:
10004040
负责人:
BRAD FORTUNE
金额:
$54.34万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-01 至 2023-07-31
关键词:
3-DimensionalAcuteAnatomyAngiographyAreaAtrophicAxonBiological MarkersBiomechanicsBlindnessBlood capillariesBlood flowCaringCellsChronicChronic DiseaseClinicalCuesCytoskeletonDataData AnalysesDevicesDiagnosisDistressDropoutEvaluationExperimental ModelsExposure toEyeFunctional disorderGlaucomaGoalsHomeostasisHumanImageImaging TechniquesIndividualInner Plexiform LayerLocationMeasurementMeasuresMethodsOptic DiskOptic NerveOptical Coherence TomographyPathologyPatientsPhysiologic Intraocular PressurePhysiologyResearch PersonnelRetinaRetinal Ganglion CellsRiskScanningSeveritiesStructureSystemTechniquesTestingTextureThinnessTimeTissuesTranslatingTransmission Electron MicroscopyVisionVisual FieldsVisual impairmentcell injuryclinical careclinical diagnosticsclinical implementationdensityin vivoinstrumentinstrumentationmaculamicroscopic imagingnext generationnonhuman primatenovelnovel markerreconstructionresearch clinical testingretinal damageretinal nerve fiber layerserial imagingsuccesstool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Currently, diagnosis of glaucoma and patient management decisions are often informed by thinning of the
optic nerve head (ONH) neuro-retinal rim, peripapillary retinal nerve fiber layer (RNFL), and macular inner
retinal layers, as detected using optical coherence tomography (OCT). These measurements are useful
because they are predictive of subsequent visual field decline, and of faster rates of subsequent thinning.
However, by the time thinning can be detected with current OCT systems, retinal ganglion cells (RGCs) and
their axons have already been lost, and therefore some impairment of visual function is unavoidable. Thus, a
key gap in the current approach to glaucoma care is the lack of reliable biomarkers that alert the clinician to
early-stage glaucomatous damage of RGCs/axons before they are permanently lost. We propose that such
information is present within OCT scans from commercially available instruments, but that additional
approaches for testing and analysis are required to reveal this information. Our overarching hypothesis is
that cues of eye-specific sensitivity to intraocular pressure (IOP) and early RGC/axon distress and
damage are present in OCT scans, and that exploiting them will provide meaningful clinical benefits.
We will use a well-established non-human primate (NHP) model of experimental glaucoma to test three
independent, but mutually supportive, hypotheses, each with its own strong potential to advance clinical care
and patient management. In Aim 1, we will test the hypothesis that larger magnitude deformations within the
ONH rim and peripapillary RNFL tissues will predict earlier and more severe loss of RGCs/axons across eyes
and locations (sectors). Specifically, in Aim 1.1, we test this prediction using the deformations resulting from
acute IOP elevation (i.e., elastic deformations or strains), and in Aim 1.2, using the deformations measured
after exposure to chronic IOP elevation (plastic deformations and remodeling). In Aim 2, we will test the
hypothesis that autoregulation dysfunction within the ONH and peripapillary RNFL tissues precedes capillary
dropout (Aim 2.1) and precedes RGCs/axon loss (Aim 2.2). In Aim 3, we will test the hypothesis that an early
stage of RGC pathology, characterized by disruption of axonal cytoskeletal ultrastructure and dendritic atrophy,
is detectable by OCT (Aim 3.1); that its onset and location are predicted by the acute and chronic deformations
determined by strain mapping (Aim 3.2); and that it represents a sign of imminent loss of RGCs/axons (Aim
3.3). Success of any one Aim would represent an important step forward in the determination of risk for
glaucoma progression in individual eyes; success of all three Aims would represent a major step forward in this
area as each biomarker could enhance the predictive capacity of the others. Moreover, because we are
conducting these studies in a species with anatomy and physiology so similar to human beings and with
standard, commercially available clinical instrumentation (OCT/OCT-angiography devices), the results could
rapidly translate to clinical testing and provide beneficial analysis tools for use by clinicians and researchers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Retinal circuit disassembly in primate glaucoma
-
批准号:10639949
-
项目类别:
-
资助金额:$75.61万
-
财政年份:2023
-
负责人:BRAD FORTUNE
-
依托单位:
Overcoming Barriers to retinal ganglion cell replacement in experimental glaucoma
-
批准号:10875042
-
项目类别:
-
资助金额:$9.34万
-
财政年份:2021
-
负责人:BRAD FORTUNE
-
依托单位:
Overcoming Barriers to retinal ganglion cell replacement in experimental glaucoma
-
批准号:10330206
-
项目类别:
-
资助金额:$139.36万
-
财政年份:2021
-
负责人:BRAD FORTUNE
-
依托单位:
Advancing OCT evaluation to reveal early-stage changes in glaucoma
-
批准号:10228613
-
项目类别:
-
资助金额:$53.03万
-
财政年份:2019
-
负责人:BRAD FORTUNE
-
依托单位:
Advancing OCT evaluation to reveal early-stage changes in glaucoma
-
批准号:10457862
-
项目类别:
-
资助金额:$52.95万
-
财政年份:2019
-
负责人:BRAD FORTUNE
-
依托单位:
Advancing OCT evaluation to reveal early-stage changes in glaucoma
-
批准号:9803604
-
项目类别:
-
资助金额:$56.89万
-
财政年份:2019
-
负责人:BRAD FORTUNE
-
依托单位:
Imaging retinal astrocytes, ganglion cells and axonal transport in vivo
-
批准号:8114960
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2011
-
负责人:BRAD FORTUNE
-
依托单位:
Imaging retinal astrocytes, ganglion cells and axonal transport in vivo
-
批准号:8306681
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2011
-
负责人:BRAD FORTUNE
-
依托单位:
Axonal cytoskeletal changes in experimental glaucoma
-
批准号:7921993
-
项目类别:
-
资助金额:$34.08万
-
财政年份:2009
-
负责人:BRAD FORTUNE
-
依托单位:
Axonal cytoskeletal changes in experimental glaucoma
-
批准号:8129511
-
项目类别:
-
资助金额:$32.72万
-
财政年份:2009
-
负责人:BRAD FORTUNE
-
依托单位:
Axonal cytoskeletal changes in experimental glaucoma
-
批准号:8762356
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2009
-
负责人:BRAD FORTUNE
-
依托单位:
Axonal cytoskeletal changes in experimental glaucoma
-
批准号:7730618
-
项目类别:
-
资助金额:$34.43万
-
财政年份:2009
-
负责人:BRAD FORTUNE
-
依托单位:
Axonal cytoskeletal changes in experimental glaucoma
-
批准号:8321570
-
项目类别:
-
资助金额:$32.72万
-
财政年份:2009
-
负责人:BRAD FORTUNE
-
依托单位:
海外基金